V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Siga Technologies Executive Compensation (FY25)

SIGA · Executive and director compensation, fiscal 2023 to 2025

The Siga Technologies brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 9, 2026Latest filing (8-K): June 10, 2026
5 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Siga Technologies brief$1,500Get the executive brief
136 figures on this page: 132 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Diem Nguyen
Latest say-on-pay support
=
June 9, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Diem Nguyen: $4,449,790 → $3,244,492 (27.1% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Siga Technologies' chief executive and what were they paid?
Diem Nguyen was paid $3,244,492 in total compensation as Chief Executive Officer and Director for fiscal 2025. Nguyen's total was 27.1% lower than the $4,449,790 reported for fiscal 2024.
What was Siga Technologies' say-on-pay result?
The say-on-pay proposal drew 95.3% of votes cast for or against in favor at the meeting held June 9, 2026 for fiscal 2025.
Which companies are in Siga Technologies' peer group?
Companies named in the disclosed peer group include Akebia Therapeutics, Inc., Aquestive Therapeutics, Collegium Pharmaceutical, Inc., CorMedix Inc. and Emergent BioSolutions, Inc., among others.
What is Siga Technologies' chief executive pay ratio?
The company reported a chief executive pay ratio of 25:1 for fiscal 2025, against median employee compensation of $128,097.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dennis Hruby
Executive Vice President and Chief Scientific Officer
◇◇◇————◇
Daniel Luckshire
Executive Vice President and Chief Financial Officer
◇◇◇————◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Diem Nguyen
Chief Executive Officer and Director
◇◇◇◇———◇
Larry Miller
General Counsel and Corporate Secretary
◇◇◇◇———◇
Daniel Luckshire
Executive Vice President and Chief Financial Officer
◇◇—————◇
Dennis Hruby
Executive Vice President and Chief Scientific Officer
◇◇—————◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Diem Nguyen
Chief Executive Officer and Director
◇◇◇————◇
Daniel Luckshire
Executive Vice President and Chief Financial Officer
◇◇◇————◇
Dennis Hruby
Executive Vice President and Chief Scientific Officer
◇◇◇————◇
Larry Miller
General Counsel and Corporate Secretary
◇◇◇◇———◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Daniel J. LuckshireRSU◇——◇——◇
Dennis E. HrubyRSU◇——◇——◇
Diem NguyenRSU◇——◇——◇
Larry MillerRSU◇——◇——◇
Larry MillerOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Diem NguyenRSU◇◇——
PSU◇◇——
PSU◇◇——
Larry MillerRSU◇◇——
PSU◇◇——
PSU◇◇——
Daniel LuckshireRSU◇◇——
PSU◇◇——
Dennis HrubyRSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
General John M. “Jack” Keane (Ret.)
◇◇◇———◇
Julian Nemirovsky
◇◇———◇◇
Joseph W. Marshall III
◇◇———◇◇
Holly L. Phillips, M.D
◇◇———◇◇
Jaymie A. Durnan
◇◇———◇◇
Harold E. Ford Jr
◇◇———◇◇
Gary J. Nabel, M.D., Ph.D
◇◇———◇◇
Evan A. Knisely
—————◇◇
Diem Nguyen, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Akebia Therapeutics, Inc. AKBA
  • Aquestive Therapeutics AQST
  • Collegium Pharmaceutical, Inc. COLL
  • CorMedix Inc. CRMD
  • Emergent BioSolutions, Inc. EBS
  • Esperion Therapeutics, Inc. ESPR
  • Eton Pharmaceuticals, Inc. ETON
  • Fennec Pharmaceuticals, Inc. FENC
  • Harmony Biosciences Holdings, Inc. HRMY
  • Heron Therapeutics, Inc. HRTX
  • Innoviva Specialty Therapeutics, Inc. INVA
  • Invivyd, Inc. IVVD
  • Ironwood Pharmaceuticals, Inc. IRWD
  • Ligand Pharmaceuticals LGND
  • Rigel Pharmaceuticals, Inc. RIGL
  • Theravance Biopharma, Inc. TBPH
  • UroGen Pharma Ltd. URGN
  • Vanda Pharmaceuticals, Inc. VNDA

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 9, 2026=◇◇◇
2022June 13, 2023=◇◇◇
2019June 16, 2020=◇◇◇
2016May 25, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Siga Technologies files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Siga Technologies disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Siga Technologies sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Siga Technologies' disclosed peer group is defensible, who names Siga Technologies back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
136 figures on this page: 132 cited to the filing that reported them, 4 calculated from figures it prints.
132 cited to the filing
4 calculated from the filing

Documents cited

  1. 0001140361-26-024780
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  2. 0001140361-26-017421
    CEO Pay Ratio · Director Compensation · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year End · and 1 more section
  3. 0001140361-23-030049
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  4. 0001140361-20-014182
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  5. 0001140361-17-022340
    Item 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Siga Technologies executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/SIGA (accessed 2026).
Short form: data: Velarion

The Siga Technologies brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Siga Technologies and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Siga Technologies discloses

The companies named in SIGA's own disclosed peer group.

Akebia Therapeutics, Inc.Aquestive TherapeuticsCollegium Pharmaceutical, Inc.CorMedix Inc.Emergent BioSolutions, Inc.Esperion Therapeutics, Inc.Eton Pharmaceuticals, Inc.Fennec Pharmaceuticals, Inc.Harmony Biosciences Holdings, Inc.Heron Therapeutics, Inc.Innoviva Specialty Therapeutics, Inc.Invivyd, Inc.Ironwood Pharmaceuticals, Inc.Ligand PharmaceuticalsRigel Pharmaceuticals, Inc.Theravance Biopharma, Inc.UroGen Pharma Ltd.Vanda Pharmaceuticals, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy